瑞信:降友邦目標價3%至116港元 維持”優於大市“評級
瑞信發表研究報吿指,友邦保險(1299.HK)將於11月12日公佈第三季業績,預期首9個月新業務價值為25.67億元美元,按實質匯率計(AER)升21%、按固定匯率基準(CER)升16%;當中單計第三季為月7.53億美元,按AER計升7%、按CER計升5%,勝市場預期。該行維持其“優於大市”評級,目標價由120港元下調3.33%至116港元。
該行指,友邦首9個月中國新業務價值按CER計按年升10%,當中第三季錄低單位數跌幅,但表現仍較同業好。另外,該行預期泰國業務將帶動東南亞第三季新業務價值增長。該行將其2021及22年盈利預測分別下調4%及2%,又預期新業務價值分別按年升20%及17%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.